Innovator U.S. Equity Ultra Buffer ETF - November (BATS: UNOV)

Latest news for Innovator U.S. Equity Ultra Buffer ETF - November (BATS:UNOV)

The Fund invests at least 80 percent of its net assets in Flexible Exchange Options (FLEX Options) that reference the SPDR S&P 500 ETF Trust (the Underlying ETF). FLEX Options are exchange-traded option contracts with uniquely customizable terms. Although guaranteed for settlement by the Options Clearing Corporation (the OCC), FLEX Options are still subject to counterparty risk with the OCC and may be less liquid than more traditional exchange-traded option contracts. Due to the unique mechanics of the Funds strategy, the return an investor can expect to receive from an investment in the Fund has characteristics that are distinct from many other investment vehicles. It is important that an investor understands these characteristics before making an investment in the Fund.

Innovator US Equity Ultra Buffer ETF - November

Innovator U.S. Equity Ultra Buffer ETF - November

On the surface, payment processing specialist BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) has no business imploding the way it did last week. On Thursday, the company posted <a href="https://www.benzinga.com/news/earnings/25/02/43547695/bill-holdings-stock-plunges-on-q2-earnings-whats-going-on">fiscal second-quarter financial results</a>, generating revenue of $362.55 million and adjusted earnings per share of 56 cents. These stats beat analysts' consensus estimates of $360.23 million and 46 cents, respectively. Nevertheless, BILL stock tanked following the results.
Even breaking down certain elements, it wasn't readily apparent for those unfamiliar with the broader context why the payment processor stumbled. For example, total revenue increased 14% year-over-year while core revenue — which consists of subscription and transaction fees — climbed 16%. Further, BILL ended the quarter with $1.57 billion in cash and cash equivalents.
Providing an intriguing framing of the results, management articulated that it is seeking "to empower small and mid-sized businesses," a segment that falls under BILL's bread and butter. The kicker was that the company raised its full-year outlook to revenue of $1.45 billion to $1.47 billion. This guidance compares favorably to the prior estimate of $1.46 billion.
Despite these seemingly stellar numbers, BILL stock imploded on Friday, begging the obvious question — why? KeyBanc analysts Alex Markgraff may have summed up the situation the best, stating that his <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43568285/bills-post-earnings-selloff-analysts-weigh-fx-headwinds-take-rate-woes">prior expectations of growth were off</a> and that BILL deserved its equity erosion. Other analysts alluded to Q3 guidance being flat rather than anything game-changing.
Generally speaking, the Q2 results were good, but concerns started to creep in about slowing sales growth. In addition, BILL's exposure to small and mid-sized businesses (SMBs) may have spooked investors, amid some fears of significant <a href="https://www.benzinga.com/news/24/12/42735416/el-erian-warns-of-hidden-crisis-in-exceptional-us-economy-as-lower-income-households-face-considerable-challenges">economic challenges</a>.
Also Read: <a href="https://www.benzinga.com/news/global/25/02/43604572/jd-vance-quarterbacking-tiktok-deal-will-his-venture-capital-experience-secure-a-win">JD Vance &#8216;Quarterbacking&#8217; TikTok Deal: Will His Venture Capital Experience Secure A Win?</a>
<h2 class="wp-block-heading">BILL Stock Now Presents a Tempting Value Proposition</h2>
Given the broader context, the question isn't so much about whether BILL stock deserved to have a reduction in the share price; rather, it's about the magnitude of the decline. Prior to the selloff, BILL traded hands near the $100 level. At time of writing, it's exchanging hands at around $65. This implosion has value hunters salivating.
Presently, BILL stock carries a trailing earnings multiple of <a href="https://finance.yahoo.com/quote/BILL/key-statistics/">over 159 times</a>. However, on a forward basis, BILL trades at just under 37 times earnings. As well, assuming revenue lands at the guidance midpoint of $1.46 billion, the equity is priced at only 4.63 times projected sales. During the first calendar quarter last year, the sales multiple averaged 6.13 times.
Yes, economic concerns linger, and BILL's exposure to SMBs presents a risk factor. However, it's also fair to point out that while the <a href="https://www.benzinga.com/news/econ-s/25/02/43565669/january-jobs-report-not-too-hot-not-too-cold-leaves-interest-rate-cuts-unlikely-expert">January jobs report</a> came in technically below expectations, overall jobs growth in December was <a href="https://www.benzinga.com/news/25/01/42934513/job-growth-fed-jitters-and-rising-mortgage-rates-this-week-in-economics">unusually strong</a>. Amid the noise within the data, some analysts argue that the labor market stands on solid ground.
Still, the most compelling argument could be the statistical data undergirding BILL stock. Using data from the past five years, BILL demonstrates an upward bias. A position entered at the beginning of the week has a 52.12% chance of rising by the end of it. Over a four-week period, the long odds improve to 54.47%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-775184" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Even more enticing, rather than viewing the data from a simple stochastic or temporal framework, one can filter the data through a dynamic lens. Last week, BILL stock dropped 33.83% — an extreme-fear event if there ever was one. Whenever BILL has lost 10% or more in a one-week period (in the past five years), there's a 60.71% chance that it will rise one week later. Over four weeks, the long odds soar to 78.57%.
<h2 class="wp-block-heading">Strategizing a Bullish Options Trade</h2>
One critical caveat to the high long odds is that the median return under the positive scenario isn't particularly remarkable. Four weeks following an extreme-fear event (losing 10% or more in one week), the median return is 8.34%. That comes out to $67.31 based on Friday's closing price, which is lower than the $69.24 target, which would be calculated using a stochastic framework.
Without getting too deep into the weeds, it's likely that market makers are anticipating a rebound in BILL stock. Therefore, the call options are probably priced at a richer-than-normal premium. Because of this situation, it may be better to consider a narrower <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a>. While this approach greatly exacerbates the risk that the entire spread will expire completely worthless, the net debit required for a wider and thereby more "protective" spread may be onerous.
With that in mind, one idea to consider is the 64/67 bull call spread (buy the $64 call, simultaneously sell the $67 call) for the options chain expiring March 7. Since BILL stock realistically has a chance of poking its head above $67 by expiration, the short call strike price gives the trader a strong chance of attaining the maximum payout (which at time of writing stands at around 87%).
Also, the $64 long call provides the potential opportunity of salvageable value if the bullish thesis doesn't quite pan out. Out of the available call spreads, the 64/67 spread may be among the most sensible given the circumstances.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43605038/coca-cola-stock-is-bubbling-higher-can-q4-earnings-keep-the-fizz-going">Coca-Cola Stock Is Bubbling Higher: Can Q4 Earnings Keep The Fizz Going?</a></li>
</ul>
Photo: Ground Picture/Shutterstock.com

Earnings Beats

Long Ideas

Options

Movers

BILL

Options Corner: Bill Holdings' Post-Earnings Implosion Gives Speculators A Discounted Long Trade

In a rapidly evolving cannabis industry, where social equity remains an ongoing challenge, Standard Wellness Maryland is making history. Led by Christina Betancourt Johnson, the company is the first African American and Latina majority-owned, vertically integrated cannabis company in the United States—as confirmed by the company with the social equity office in Maryland.
Now, with the opening of The Forest in Baltimore's Canton neighborhood, Johnson and her team are bringing their vision of wellness, community and representation to life.
&#8220;We are incredibly honored to break new ground in Maryland&#8217;s retail cannabis landscape,&#8221; said Johnson, who also serves as the company's CEO. "Our promise is to promote wellness and empower our community by being a trusted source for holistic well-being."
<h3 class="wp-block-heading">A Business Rooted In Representation</h3>
The Forest represents the culmination of years of effort to create opportunities in an industry that has historically marginalized people of color. The cannabis sector, despite its multi-billion-dollar valuation, still sees <a href="https://mjbizdaily.com/women-minority-cannabis-executives-rebound-to-pre-pandemic-levels/">minority ownership as an exception rather than the rule</a>. The launch of The Forest is a tangible step toward reversing that imbalance.
"This moment is not just about one business—it's a step toward leveling the playing field and fostering inclusive growth across our economy," said Delegate C.T. Wilson, chairman of the Economic Matters Committee and co-sponsor of Maryland's House Bill 556, which established <a href="https://www.benzinga.com/cannabis">adult-use cannabis</a> in the state.
For Johnson, representation isn't just about ownership, it's about creating an ecosystem where diverse voices shape the industry. With leadership positions on the U.S. Cannabis Council and the National Hispanic Cannabis Council, as well as a role as vice chair of The Maryland Wholesale Cannabis Trade Association (CANMD), she has been a consistent advocate for minority participation in the cannabis space.
Her work caught the attention of Maryland's governor, Wes Moore, who appointed her to the Advisory Board on Medical and Adult-Use Cannabis, a key regulatory body shaping the future of cannabis in the state.
<h3 class="wp-block-heading">The Forest: A Dispensary Designed For Community</h3>
In Baltimore's historic Canton neighborhood, The Forest is more than a retail location. It's a wellness hub where customers can explore cannabis in a welcoming, education-focused environment. With a carefully curated selection of high-quality, sustainable products, the dispensary serves both medical patients and adult-use consumers, prioritizing their needs with a thoughtful approach.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10134419/The-Forest_008_PhotoCredit_TeemingVisions-1024x683.jpeg" alt="" class="wp-image-775111" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10134419/The-Forest_008_PhotoCredit_TeemingVisions-1024x683.jpeg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10134419/The-Forest_008_PhotoCredit_TeemingVisions-300x200.jpeg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10134419/The-Forest_008_PhotoCredit_TeemingVisions-768x512.jpeg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10134419/The-Forest_008_PhotoCredit_TeemingVisions-1536x1025.jpeg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10134419/The-Forest_008_PhotoCredit_TeemingVisions.jpeg 1619w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
"The Forest is where everyone can pursue their wellness journey with support and empowerment," Johnson explained.
From the start, The Forest prioritized building relationships with the local community. Amanda Bourgeois, president of the Canton Community Association, recognized the company&#8217;s efforts early on.
"The Forest Dispensary has taken a thoughtful approach to becoming a valued partner within our community by engaging with the Canton Community Association early on," she said. "Their commitment to total wellness and collaboration reflects a dedication to contributing meaningfully to both our neighborhood and the broader Baltimore community."
<h3 class="wp-block-heading">A Grand Opening With Purpose</h3>
The grand opening of The Forest earlier this year was a ribbon-cutting ceremony that carried deeper significance—a celebration of perseverance and progress. The event brought together lawmakers, local leaders and the community for speeches, live entertainment, meet-and-greets and a showcase of local food vendors.
For many, this new business stands as a testament to what's possible when equity initiatives take root and create real opportunities.
"When businesses like these thrive, so does the broader community," said Wilson.
As cannabis continues its march toward mainstream acceptance, Standard Wellness Maryland is setting a precedent. With a clear mission, deep community ties and an unwavering commitment to equity, The Forest is making history while actively shaping the future of the industry.
Photo by Teeming Visions, courtesy of Standard Wellness Maryland

Cannabis

News

Retail Sales

Inside The First Black And Latina-Owned Vertically Integrated Cannabis Company In The US

In the latest quarter, 26 analysts provided ratings for Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cloudflare and provided 12-month price targets. The average target is $145.08, accompanied by a high estimate of $185.00 and a low estimate of $68.00. Surpassing the previous average price target of $111.38, the current average has increased by 30.26%.
<img src="https://www.benzinga.com/files/images/story/2025/1739217664_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Cloudflare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Aaron Samuels</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$149.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$183.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$180.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Sell</td>
<td>$68.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$110.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Matt Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$125.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cloudflare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Cloudflare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cloudflare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Cloudflare's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NET/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cloudflare analyst ratings.</a>
<h2>All You Need to Know About Cloudflare</h2>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
<h3>Unraveling the Financial Story of Cloudflare</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Cloudflare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Cloudflare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -3.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cloudflare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cloudflare's ROA excels beyond industry benchmarks, reaching -0.51%. This signifies efficient management of assets and strong financial health.
Debt Management: Cloudflare's debt-to-equity ratio is below the industry average at 1.49, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Cloudflare: Insights From 26 Analyst Reviews

5 analysts have expressed a variety of opinions on CNO Finl Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CNO Finl Group, presenting an average target of $42.8, a high estimate of $46.00, and a low estimate of $38.00. This upward trend is evident, with the current average reflecting a 5.68% increase from the previous average price target of $40.50.
<img src="https://www.benzinga.com/files/images/story/2025/1739217647_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of CNO Finl Group's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$41.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CNO Finl Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CNO Finl Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into CNO Finl Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CNO Finl Group analyst ratings.</a>
<h2>Discovering CNO Finl Group: A Closer Look</h2>
CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
<h3>CNO Finl Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: CNO Finl Group's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 19.21%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.82%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CNO Finl Group's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): CNO Finl Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: CNO Finl Group's debt-to-equity ratio stands notably higher than the industry average, reaching 1.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About CNO Finl Group

17 analysts have expressed a variety of opinions on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $149.24, along with a high estimate of $190.00 and a low estimate of $116.00. This upward trend is apparent, with the current average reflecting a 2.88% increase from the previous average price target of $145.06.
<img src="https://www.benzinga.com/files/images/story/2025/1739217639_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axsome Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Get to Know Axsome Therapeutics Better</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Axsome Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 81.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Axsome Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -61.67%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -66.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.64%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock

During the last three months, 36 analysts shared their evaluations of Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">6</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Tesla, presenting an average target of $362.72, a high estimate of $550.00, and a low estimate of $24.86. This upward trend is apparent, with the current average reflecting a 20.94% increase from the previous average price target of $299.91.
<img src="https://www.benzinga.com/files/images/story/2025/1739217629_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Tesla by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$474.00</td>
<td>$492.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$259.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$515.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$373.00</td>
<td>$351.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$425.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$365.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$325.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$490.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$492.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Chris McNally</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$275.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$404.00</td>
<td>$298.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$351.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$24.86</td>
<td>$24.86</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$480.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$515.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$345.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$365.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Edison Yu</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Sell</td>
<td>$175.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$411.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$226.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$313.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Philippe Houchois</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$300.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tesla. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tesla compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Tesla's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Tesla's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TSLA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tesla analyst ratings.</a>
<h2>All You Need to Know About Tesla</h2>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and offer a robotaxi service. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
<h3>Unraveling the Financial Story of Tesla</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Tesla's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.15%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tesla's net margin excels beyond industry benchmarks, reaching 9.0%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Tesla's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.24%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.91%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.19.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TSLA

Where Tesla Stands With Analysts

Dollar Gen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) short percent of float has fallen 7.13% since its last report. The company recently reported that it has 10.13 million shares sold short, which is 5.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Gen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739217623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Gen has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dollar Gen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Gen's peer group average for short interest as a percentage of float is 3.97%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(DG) - Analyzing Dollar Gen's Short Interest

Ratings for Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $23.75, a high estimate of $25.00, and a low estimate of $23.00. Observing a 6.36% increase, the current average has risen from the previous average price target of $22.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1739217621_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Mach Natural Resources is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mach Natural Resources. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Mach Natural Resources compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Mach Natural Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Mach Natural Resources's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MNR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Mach Natural Resources analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Mach Natural Resources</h2>
Mach Natural Resources LP is an independent upstream oil and gas company focused on the acquisition, development and production of oil, natural gas and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas and the panhandle of Texas.
<h3>A Deep Dive into Mach Natural Resources's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Mach Natural Resources displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 45.7%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Mach Natural Resources's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.39% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Mach Natural Resources's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 5.77%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Mach Natural Resources's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.96%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Mach Natural Resources's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.64, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Mach Natural Resources Stock

Lockheed Martin's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) short percent of float has fallen 9.87% since its last report. The company recently reported that it has 2.73 million shares sold short, which is 1.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lockheed Martin Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739217618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lockheed Martin has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Lockheed Martin's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lockheed Martin's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Lockheed Martin's Recent Short Interest

Analysts' ratings for Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high estimate of $83.00, and a low estimate of $74.00. This current average represents a 1.4% decrease from the previous average price target of $78.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1739217614_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Equity Residential among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$78.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Equity Residential. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Equity Residential compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Equity Residential's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Equity Residential's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EQR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Equity Residential analyst ratings.</a>
<h2>Delving into Equity Residential's Background</h2>
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
<h3>Equity Residential: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Equity Residential's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 2.46%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Equity Residential's net margin is impressive, surpassing industry averages. With a net margin of 54.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Equity Residential's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.83% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Equity Residential's ROA excels beyond industry benchmarks, reaching 2.01%. This signifies efficient management of assets and strong financial health.
Debt Management: Equity Residential's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.76.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Equity Residential Stock: Analyst Perspectives (6 Ratings)

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 3.13% since its last report. The company recently reported that it has 38.07 million shares sold short, which is 29.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739217612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 15.25%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NVAX

(NVAX) - Analyzing Novavax's Short Interest

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) has outperformed the market over the past 20 years by 3.94% on an annualized basis producing an average annual return of 12.35%. Currently, Ross Stores has a market capitalization of $47.04 billion. 
Buying $1000 In ROST: If an investor had bought $1000 of ROST stock 20 years ago, it would be worth $10,302.42 today based on a price of $142.59 for ROST at the time of writing.
<h3>Ross Stores's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739217610_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROST

Here's How Much You Would Have Made Owning Ross Stores Stock In The Last 20 Years

Oil prices climbed Monday, marking their strongest one-day surge in nearly a month, as geopolitical risks intensified following threats of a <a href="https://www.benzinga.com/topic/gaza">ceasefire breakdown in Gaza.</a>
West Texas Intermediate crude futures jumped 1.8% to $71.90 per barrel by 2:30 p.m. ET, while Brent crude advanced 1.6% to $76.40 per barrel. The rally came as investors weighed the potential for renewed instability in the Middle East, a region responsible for nearly one-third of global oil production.
U.S. energy stocks also gained traction, with the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rising 2%, while oil majors Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) climbed 1.6% and 0.8%, respectively.
<h3 class="wp-block-heading">Ceasefire At Risk: Hamas Accuses Israel Of Violations</h3>
Concerns over escalating conflict in Gaza grew after Hamas announced it would halt hostage releases, citing Israel's alleged failure to uphold the terms of the ceasefire.
Two Egyptian security sources told Reuters that mediators now fear a collapse in the deal, which was intended to facilitate a phased exchange of hostages and prisoners.
Since the agreement took effect in early January, Hamas has freed 18 captives, including dual U.S.-Israeli citizen Keith Siegel, in exchange for more than 730 Palestinian prisoners.
Yet, the next scheduled swap — three Israeli hostages for hundreds of Palestinian detainees — has now been delayed.
The fragile six-week ceasefire, which began in mid-January, was designed to facilitate the release by Hamas of Israeli hostages captured in its Oct. 7 attack in exchange for Palestinian prisoners held by Israel.
<h3 class="wp-block-heading">Trump's Middle East Strategy: What's Next For Gaza?</h3>
President Donald Trump, less than a month into his second term, has sent global shockwaves with his stance on Gaza. Over the weekend, he floated the idea of U.S. ownership of the war-ravaged enclave, describing it as a potential economic hub.
Speaking aboard Air Force One on Sunday, Trump suggested that Gaza could be bought and owned with assistance from regional partners.
"I&#8217;m committed to buying and owning Gaza&#8230;We&#8217;ll make it into a very good site for future development,&#8221; he said.
Last week, in a meeting with Israeli Prime Minister Benjamin Netanyahu, Trump suggested the United States assume control of the Gaza Strip. His proposal included relocating the roughly 2 million Palestinian residents to nearby nations like Egypt and Jordan, envisioning Gaza's transformation into the &#8220;Riviera of the Middle East.&#8221;
Trump said that Palestinians displaced from Gaza would not have the right to return under his proposal. 
Trump's suggestion sparked significant international criticism. United Nations Secretary-General António Guterres cautioned against any measures that could be interpreted as ethnic cleansing.
Egypt and Jordan have firmly rejected the idea of resettling Palestinians from Gaza, citing concerns over regional stability and potential demographic shifts.
Read Next:
<a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43599094/stock-of-the-day-tariffs-could-mean-a-new-bull-market-for-cleveland-cliffs">Stock Of The Day: Tariffs Could Mean A New Bull Market For Cleveland Cliffs</a>
Photo via Shutterstock.

Sector ETFs

Commodities

Politics

Global

Econ #s

Markets

ETFs

Oil Prices, Energy Stocks Jump As Gaza Ceasefire Risks Collapse On Rising Hamas-Israel Tensions

Health insurance company Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is set to release its fourth-quarter 2024 earnings report on Feb. 11, before market hours. The stock has dropped 2.37% from the previous close, as of writing, on Feb.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
The stock is up 5.58% year-to-date but has fallen 27.73% in the past year.
In the previous quarter, Humana reported revenues of $29.4 billion — a 15.2% year-over-year increase. It surpassed analysts&#8217; expectations by 2.6%. 
The company also achieved a solid beat on earnings per share (EPS) estimates, though it slightly missed full-year EPS guidance estimates.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43600652/super-micro-computer-q2-earnings-preview-accounting-updates-nasdaq-deadline-on-watch">Super Micro Computer Q2 Earnings Preview: Accounting Updates, Nasdaq Deadline On Watch</a>
What To Watch: For the upcoming report, analysts anticipate a 12% year-over-year revenue growth to $28.83 billion. This indicates a deceleration from the 14.7% growth observed in the same quarter last year. An adjusted loss of $2.12 per share is expected.
It&#8217;s noteworthy that some of Humana&#8217;s peers in the health insurance sector have already reported their Q4 results. Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) delivered a 3.4% year-over-year revenue growth, beating analysts&#8217; expectations by 4.4%, while Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported a 12.8% increase, topping estimates by 5.2%. 
Investors will be keen to see if Humana can maintain its growth trajectory and how its performance compares to industry peers. Additionally, any updates on operating cost ratios will be closely monitored, especially after the company projected a 30 basis point decrease in its adjusted operating cost ratio for the year during the Q3 earnings call.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43604305/what-to-expect-when-biotech-giant-gilead-reports-q4-earnings-on-tuesday">What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?</a></li>
</ul>
Photo: Shutterstock<a href="https://press.humana.com/news/news-details/2025/Humana-Inc.-to-Release-Fourth-Quarter-2024-Results-on-February-11-2025/default.aspx?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"></a>

Previews

Humana Earnings On Deck: Investors Brace For Slower Growth Clip

Indoor cannabis cultivation in the United States consumes more energy than all outdoor agriculture combined, primarily due to the need for specialized lighting, climate control and ventilation systems. This high energy demand is exacerbated by legal requirements mandating in-state production, which often leads to reliance on <a href="https://www.benzinga.com/cannabis">energy-intensive indoor facilities.</a>
Despite the industry&#8217;s rapid growth, there has been limited focus on its environmental impact. A recent <a href="https://www.sciencedirect.com/science/article/pii/S2590332225000053">study</a> undertaken by Evan Mills of the Energy and Resources Group of UC Berkeley, points out that indoor cultivation accounts for approximately two-thirds of U.S. marijuana production and is a major emitter of greenhouse gases. For instance, producing four pounds of cannabis in an indoor facility can consume as much electricity as an average American home uses in a year.
Indoor cultivation is also far more energy intensive than more familiar building types and manufacturing processes, says Mills. &#8220;For comparison, while a typical cannabis plant factory is similar in size to an average Walmart, it uses ∼100 times more energy. Energy use per unit floor area is ∼600 times that of conventional storage warehouses and ∼40 times that of energy-intensive hospitals. Energy use per unit weight is ∼200 times that of manufacturing best practices for aluminum, ∼2,200:1 for blast furnace steel, and ∼10,500:1 for Portland cement.&#8221;
Read Next: <a href="https://www.benzinga.com/news/global/25/02/43600852/china-sets-sights-on-us-tech-companies-as-trade-tensions-rise">China Sets Sights On Apple, Nvidia And Other US Tech Companies As Trade Tensions Rise</a>
<h2 class="wp-block-heading">Greenwashing</h2>
Mills estimates that both legal and illegal marijuana cultivation operations in the U.S. consume about 596 petajoules of energy annually. "Consumers are led to believe that this is ‘nature's medicine' and that it's ‘green' in every sense of the word. There's lots of greenwashing."
Several electric utility companies are involved in supplying energy to indoor marijuana cultivation facilities. For example, Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>), which operates in Colorado, has experienced significant load growth due to the cannabis industry.
Since March 2017, California&#8217;s PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) declared business customers eligible for service under an agricultural rate plan that included customers who grow cannabis outdoors and those who grow indoors in commercial greenhouses.
Both California and Colorado have had legal marijuana for over a decade and are major producers of indoor weed. 
<h2 class="wp-block-heading">Final Word</h2>
Meanwhile, says Mills, a research gap and the industry&#8217;s ineligibility to benefit from federal incentives highlight opportunities for local action. Given the significant impact of cannabis consumption and product types on emissions, &#8220;it is high time for drug policy and environmental policy to be harmonized.&#8221;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/events/25/02/43591841/brittney-griner-and-ricky-williams-headline-women-grow-2025-leadership-summit-key-event-for-the-cannabis-industry">Brittney Griner And Ricky Williams Headline Women Grow 2025 Leadership Summit, Key Event For Cannabis Industry</a></li>
</ul>
Photo: Shutterstock

Cannabis Grow Facilities Consume 100 Times More Energy Than The Average Walmart

The Department of Government Efficiency (D.O.G.E) meme coin has rebounded, with <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42858673/millionaire-trader-shares-playbook-he-used-to-print-8-figure-profits-on-d-o-g-e-bonk">prominent advocate Unipcs</a> suggesting the real rally is just starting. &nbsp;
What Happened: Unipcs <a href="https://x.com/theunipcs/status/1888660696230957486">noted</a> on Monday on X that the largest holder of Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) tokens is reportedly making big moves into D.O.G.E.
Despite D.O.G.E being down 88% from its all-time highs, the PEPE whale—known as dimethyltryptamine.eth—invested 97.22 ETH into D.O.G.E in a single transaction, signaling confidence in its future potential.
Crypto copy trader DrolbyGames explained that this whale is <a href="https://x.com/drolbygames/status/1888562821266280593">famous</a> for buying PEPE tokens for just $52, which are now valued at over $20.5 million. 
With nearly $19 million still tied to PEPE and newly linked to D.O.G.E, the question arises whether this whale know ssomething others don&#8217;t about this $45 million valuation meme coin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43390075/department-of-government-efficiency-meme-coin-plummets-30-as-attention-pivots-to-trump">Department Of Government Efficiency Meme Coin Plummets 30% As Attention Pivots To TRUMP</a>
What's Next: &nbsp;Despite a 63% drop in the last month, crypto trader EuroSniper believes that D.O.G.E is gearing up for its real rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> &#8211; Department of Government Efficiency. Nearly x2 up from the lows already. The start the real DOGE run&#x1f3af; <a href="https://t.co/x39nXtFvMv">pic.twitter.com/x39nXtFvMv</a>
&mdash; €ｕｒｏＳｎｉｐｅｒ (@TheEuroSniper) <a href="https://twitter.com/TheEuroSniper/status/1888952619281891442?ref_src=twsrc%5Etfw">February 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Unipcs noted that 80-90% corrections are common for meme coins like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), but the true test is whether the coin&#8217;s narrative remains strong. 
In this case, D.O.G.E is hitting all the right notes with strong on-chain metrics and a dedicated community, setting the stage for a potential breakout.
With all these factors aligning, it seems that D.O.G.E is poised for growth, with Unipcs calling it a coin "hitting all the right notes."
Read Next: &nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43586084/trump-shib-doge-or-xrp-whats-your-best-bet-in-a-new-trading-week-heres-what-the-indicators-tell-us">TRUMP, SHIB, DOGE or XRP — What&#8217;s Your Best Bet In A New Trading Week? Here&#8217;s What The Indicators Tell Us</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

D.O.G.E Rallies 16% As Pepe Coin Whale Spotted Accumulating Significant Amounts

Amid all the tariff drama and AI hype, the UK's equity market has been left for dead. That's exactly what makes it interesting right now.
While everyone else is chasing expensive U.S. tech stocks, the real value is hiding in plain sight—UK small caps. The setup here is simple: deep undervaluation, an improving macro backdrop, and a market that's so unloved it's primed for a sharp re-rating.
Smart investors who step in now could be handsomely rewarded.
Let me show you two of the best plays to make here right now.
Right now, UK small-cap stocks are trading at fire-sale prices. The FTSE SmallCap Index and AIM market are stuck at price-to-earnings (P/E) ratios that are downright ridiculous. The FTSE SmallCap Index is going for a forward P/E of around 10x—well below its long-term average of 14x. The price-to-book (P/B) ratio? Just 1.1x, compared to the historical 1.6x. This is a screaming deal, and history tells us that discounts this deep don't last forever. Sooner or later, the market wakes up.
The UK economy has been through the wringer, but there are signs of stabilization. The Bank of England is shifting gears, hinting at rate cuts in 2025. That's exactly the kind of catalyst small-cap stocks need. These companies are more sensitive to interest rates, and as borrowing costs fall, they'll get a tailwind. The last time we saw this kind of setup, small caps staged a powerful comeback. There's no reason to think history won't repeat itself.
For years, Brexit and economic worries battered the British pound, making UK stocks less attractive to global investors. But that's changing. The currency has stabilized, and as confidence returns, so will foreign capital. The best part? With UK stocks trading at multi-year discounts, international money managers will have no choice but to start paying attention. And when they do, prices will move up fast.
Smart money knows a deal when they see one. In 2024 alone, over £50 billion worth of UK-listed companies were snapped up by private equity and institutional investors. And the trend isn't slowing down—some analysts expect that up to a third of smaller companies on the AIM market could be takeover targets in 2025. If private equity sharks are circling, it's a sure sign of value. If you buy in before the deals accelerate, you could be looking at serious upside.
Right now, investor sentiment toward UK stocks is in the gutter. That's the best time to buy. Every cycle has a turning point, and we may be at one now. As global capital starts looking for value again, UK small caps—beaten down and ignored—will be the perfect hunting ground. Those who get in early will be rewarded when the herd finally catches on.
This isn't a flashy, momentum-driven trade—it's a classic value investor's dream. UK small-cap stocks are dirt cheap, the macro picture is shifting in their favor, and the market is asleep at the wheel. When conditions like this appear, the play is simple: step in, buy quality businesses at a discount, and let time do the heavy lifting. If history is any guide, those who buy now will be glad they did when the market finally wakes up.
One stock that absolutely deserves a closer look is Navigator Holdings Ltd (NVGS). This company operates a fleet of liquefied gas carriers, a sector benefiting from rising global energy trade. Despite strong fundamentals, Navigator is trading at a discount, with a price-to-earnings ratio below 10x and a price-to-book ratio under 1.2x. Demand for liquefied gases is expected to remain robust, and the company's long-term contracts provide earnings visibility. With a strong balance sheet and increasing free cash flow, Navigator Holdings is an undervalued asset in a sector poised for continued growth. Investors looking for a well-priced, high-potential play should be taking a serious position in NVGS before the broader market catches on.
Another stock that deserves investor attention is Gambling.com Group (GAMB). This online gaming and betting affiliate platform is capitalizing on the expansion of regulated online gambling markets worldwide. With strong profitability, high margins, and impressive revenue growth, GAMB is proving its ability to generate consistent earnings. The company's scalable model and disciplined cost management make it a high-quality asset in an industry with strong tailwinds. As online gambling continues to gain traction, Gambling.com Group is positioned for long-term success, making it a solid buy for investors looking for exposure to a lucrative and expanding market.
UK small-cap stocks are an absolute steal right now. We have deep discounts, improving economic conditions, and a shift in investor sentiment right around the corner. The last time we saw these kinds of valuations, the returns were explosive for those who got in early.&nbsp;
The smart money is already moving, and if you are serious about compounding capital, this is an opportunity you don&#8217;t want to miss.&nbsp;
The time to act is now—before the rest of the world wakes up to what's happening.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0213&amp;utm_campaign=wallstreetadvantage">The Only Membership With a Positive ROI</a>
Gain your competitive Edge in markets with a steady stream of new stock ideas, proprietary data, and expert insights. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0213&amp;utm_campaign=wallstreetadvantage">Get started right here.</a>
Image via Shutterstock

Opinion

Buy These 2 Great Stocks at Fire-Sale Prices While You Still Can

Coupang's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 14.14 million shares sold short, which is 1.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Coupang Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739216723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Coupang has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Coupang's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Coupang's peer group average for short interest as a percentage of float is 9.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CPNG

Peering Into Coupang's Recent Short Interest

Cushman &amp; Wakefield's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) short percent of float has risen 3.87% since its last report. The company recently reported that it has 14.40 million shares sold short, which is 7.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cushman &amp; Wakefield Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739216718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cushman &amp; Wakefield has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cushman &amp; Wakefield's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cushman &amp; Wakefield's peer group average for short interest as a percentage of float is 5.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cushman & Wakefield's Recent Short Interest

ASGN's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) short percent of float has risen 4.76% since its last report. The company recently reported that it has 2.06 million shares sold short, which is 6.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ASGN Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739216713_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ASGN has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ASGN's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ASGN's peer group average for short interest as a percentage of float is 3.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Innovator U.S. Equity Ultra Buffer ETF - November

News

Latest news for Innovator U.S. Equity Ultra Buffer ETF - November (BATS:UNOV)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga